Limits...
Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats

View Article: PubMed Central - PubMed

ABSTRACT

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease in humans constituting a major health concern today whose prevalence has been increasing over the world. Production of reactive oxygen species (ROS) and disturbed capacity of antioxidant defense in IBD subjects have been reported. Antioxidants may play a significant role in IBD treatment. This study aimed at evaluating ameliorative effects of intraperitoneal resveratrol pretreatment on trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. Thirty five Wistar-Albino female rats were divided equally into five groups. Inflammation was induced by the intrarectal administration of TNBS under anesthesia. Intraperitoneal administration of resveratrol (RSV) at a concentration of 10mg/kg/day for 5 days before the induction of colitis significantly reduced microscopy score and malondialdehyde (MDA) levels and increased glutathione peroxidase (GSH Px) activity compared to TNBS and vehicle groups. Also an insignificant increase in catalase (CAT) activity was observed in the RSV treated group compared to TNBS and vehicle groups. In this paper, the most recent patent on the identification and treatment of IBD was indicated. In conclusion, antioxidant RSV proved to have a beneficial effect on TNBS colitis in rats. In light of these advantageous results, the RSV can be considered as adjuvant agent in IBD treatments.

No MeSH data available.


Related in: MedlinePlus

Histopathological features of the colon associated with colitis and the effects of Resveratrol (RSV) on colon injury. (A) Resveratrol (noncolitis) group (normal histological appearance of rat colonic mucosa), (B) Sham group (no histological modification), (C) TNBS-induced colitis group (widespread necrosis and diffuse infiltration of inflammatory cells in the mucosa- submucosa and submucosal edema), (D) TNBS colitis + DMSO group (similar pattern to TNBS colitis with evident diffuse hemorrhage), (E) TNBS colitis + Resveratrol (10mg/kg) group (diminished findings of the tissue injury, inflammation and edema in the colonic mucosa). Mucosal injury was produced by TNBS administration (25mg/animal), characterized by necrosis of epithelium, focal ulceration of the mucosa and diffuse infiltration of inflammatory cells in mucosa and submucosa as well as submucosal edema. Treatment with Resveratrol (10mg/kg) reduced the the morphological changes associated with TNBS administration protecting the mucosal architecture (Fig. 2E & 2F). Original magnifications was 100 x for all groups (A-E) on Hematoxylin and eosin stained slides.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4997944&req=5

Figure 2: Histopathological features of the colon associated with colitis and the effects of Resveratrol (RSV) on colon injury. (A) Resveratrol (noncolitis) group (normal histological appearance of rat colonic mucosa), (B) Sham group (no histological modification), (C) TNBS-induced colitis group (widespread necrosis and diffuse infiltration of inflammatory cells in the mucosa- submucosa and submucosal edema), (D) TNBS colitis + DMSO group (similar pattern to TNBS colitis with evident diffuse hemorrhage), (E) TNBS colitis + Resveratrol (10mg/kg) group (diminished findings of the tissue injury, inflammation and edema in the colonic mucosa). Mucosal injury was produced by TNBS administration (25mg/animal), characterized by necrosis of epithelium, focal ulceration of the mucosa and diffuse infiltration of inflammatory cells in mucosa and submucosa as well as submucosal edema. Treatment with Resveratrol (10mg/kg) reduced the the morphological changes associated with TNBS administration protecting the mucosal architecture (Fig. 2E & 2F). Original magnifications was 100 x for all groups (A-E) on Hematoxylin and eosin stained slides.

Mentions: The results of the histological examination showed that while there was no difference between the microscopic injury scores of the TNBS colitis (9.43 + 1. 51) and the vehicle (TNBS + DMSO) groups (9.29 + 0.76, P >0.05), the microscopic injury scores of the RSV (0.83 + 0.75) and Sham (0.83 + 0.41) groups were significantly different from the microscopic injury scores of TNBS colitis and the vehicle groups (P < 0,01) Fig. (1 & 2). Treatment with the RSV (6.29 + 1.50) resulted in a substantially lower microscopic injury score compared to that in the TNBS-induced colitis and vehicle-treated groups (P< 0.01) Fig. (1 & 2).There was no marked difference for the microscopic injury scores between the RSV and Sham groups (P > 0.05), Fig. (1).


Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats
Histopathological features of the colon associated with colitis and the effects of Resveratrol (RSV) on colon injury. (A) Resveratrol (noncolitis) group (normal histological appearance of rat colonic mucosa), (B) Sham group (no histological modification), (C) TNBS-induced colitis group (widespread necrosis and diffuse infiltration of inflammatory cells in the mucosa- submucosa and submucosal edema), (D) TNBS colitis + DMSO group (similar pattern to TNBS colitis with evident diffuse hemorrhage), (E) TNBS colitis + Resveratrol (10mg/kg) group (diminished findings of the tissue injury, inflammation and edema in the colonic mucosa). Mucosal injury was produced by TNBS administration (25mg/animal), characterized by necrosis of epithelium, focal ulceration of the mucosa and diffuse infiltration of inflammatory cells in mucosa and submucosa as well as submucosal edema. Treatment with Resveratrol (10mg/kg) reduced the the morphological changes associated with TNBS administration protecting the mucosal architecture (Fig. 2E & 2F). Original magnifications was 100 x for all groups (A-E) on Hematoxylin and eosin stained slides.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4997944&req=5

Figure 2: Histopathological features of the colon associated with colitis and the effects of Resveratrol (RSV) on colon injury. (A) Resveratrol (noncolitis) group (normal histological appearance of rat colonic mucosa), (B) Sham group (no histological modification), (C) TNBS-induced colitis group (widespread necrosis and diffuse infiltration of inflammatory cells in the mucosa- submucosa and submucosal edema), (D) TNBS colitis + DMSO group (similar pattern to TNBS colitis with evident diffuse hemorrhage), (E) TNBS colitis + Resveratrol (10mg/kg) group (diminished findings of the tissue injury, inflammation and edema in the colonic mucosa). Mucosal injury was produced by TNBS administration (25mg/animal), characterized by necrosis of epithelium, focal ulceration of the mucosa and diffuse infiltration of inflammatory cells in mucosa and submucosa as well as submucosal edema. Treatment with Resveratrol (10mg/kg) reduced the the morphological changes associated with TNBS administration protecting the mucosal architecture (Fig. 2E & 2F). Original magnifications was 100 x for all groups (A-E) on Hematoxylin and eosin stained slides.
Mentions: The results of the histological examination showed that while there was no difference between the microscopic injury scores of the TNBS colitis (9.43 + 1. 51) and the vehicle (TNBS + DMSO) groups (9.29 + 0.76, P >0.05), the microscopic injury scores of the RSV (0.83 + 0.75) and Sham (0.83 + 0.41) groups were significantly different from the microscopic injury scores of TNBS colitis and the vehicle groups (P < 0,01) Fig. (1 & 2). Treatment with the RSV (6.29 + 1.50) resulted in a substantially lower microscopic injury score compared to that in the TNBS-induced colitis and vehicle-treated groups (P< 0.01) Fig. (1 & 2).There was no marked difference for the microscopic injury scores between the RSV and Sham groups (P > 0.05), Fig. (1).

View Article: PubMed Central - PubMed

ABSTRACT

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease in humans constituting a major health concern today whose prevalence has been increasing over the world. Production of reactive oxygen species (ROS) and disturbed capacity of antioxidant defense in IBD subjects have been reported. Antioxidants may play a significant role in IBD treatment. This study aimed at evaluating ameliorative effects of intraperitoneal resveratrol pretreatment on trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. Thirty five Wistar-Albino female rats were divided equally into five groups. Inflammation was induced by the intrarectal administration of TNBS under anesthesia. Intraperitoneal administration of resveratrol (RSV) at a concentration of 10mg/kg/day for 5 days before the induction of colitis significantly reduced microscopy score and malondialdehyde (MDA) levels and increased glutathione peroxidase (GSH Px) activity compared to TNBS and vehicle groups. Also an insignificant increase in catalase (CAT) activity was observed in the RSV treated group compared to TNBS and vehicle groups. In this paper, the most recent patent on the identification and treatment of IBD was indicated. In conclusion, antioxidant RSV proved to have a beneficial effect on TNBS colitis in rats. In light of these advantageous results, the RSV can be considered as adjuvant agent in IBD treatments.

No MeSH data available.


Related in: MedlinePlus